Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 31, 2025 | Press Releases

– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 –...

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Mar 30, 2025 | Press Releases

CUPERTINO, Calif., March 30, 2025 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and...

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025 | Press Releases

CUPERTINO, Calif., Feb. 04, 2025 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025 | Press Releases

CUPERTINO, Calif., Jan. 30, 2025 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025 | Press Releases

CUPERTINO, Calif., Jan. 07, 2025 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...